Amgen Inc. (NASDAQ:AMGN) Shares Sold by Proquility Private Wealth Partners LLC

Proquility Private Wealth Partners LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 13.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,890 shares of the medical research company’s stock after selling 456 shares during the period. Proquility Private Wealth Partners LLC’s holdings in Amgen were worth $753,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. XTX Topco Ltd purchased a new stake in Amgen in the 2nd quarter worth approximately $661,000. Certified Advisory Corp lifted its stake in shares of Amgen by 16.0% in the 2nd quarter. Certified Advisory Corp now owns 1,460 shares of the medical research company’s stock valued at $456,000 after purchasing an additional 201 shares during the period. Steel Grove Capital Advisors LLC boosted its holdings in Amgen by 5.8% during the second quarter. Steel Grove Capital Advisors LLC now owns 1,357 shares of the medical research company’s stock worth $424,000 after buying an additional 74 shares in the last quarter. Public Sector Pension Investment Board grew its position in Amgen by 74.2% during the second quarter. Public Sector Pension Investment Board now owns 20,647 shares of the medical research company’s stock valued at $6,451,000 after buying an additional 8,795 shares during the period. Finally, Evergreen Capital Management LLC increased its holdings in Amgen by 2.5% in the second quarter. Evergreen Capital Management LLC now owns 9,057 shares of the medical research company’s stock valued at $2,830,000 after buying an additional 225 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent analyst reports. Royal Bank of Canada lowered their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Barclays boosted their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Sanford C. Bernstein initiated coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $314.91.

Amgen Stock Up 1.0 %

Shares of NASDAQ:AMGN opened at $274.81 on Wednesday. The firm’s 50-day moving average is $272.95 and its two-hundred day moving average is $306.92. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market capitalization of $147.72 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business earned $4.96 EPS. Analysts predict that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.